NasdaqGS:GILDBiotechs
How Gilead’s Lenacapavir Launch and New HIV Data May Shape GILD’s Global Outlook
Gilead Sciences recently announced the first shipments of its twice-yearly injectable HIV prevention medicine, lenacapavir, to Eswatini and Zambia, while also sharing positive Phase 3 results for a once-daily HIV regimen combining bictegravir and lenacapavir.
These developments highlight Gilead’s rapid progress in expanding access to innovative HIV prevention therapies in regions most affected by the disease and reinforce the company’s position in HIV treatment innovation.
We’ll examine how...